Table 1

Patient baseline characteristics

Treatment/study, year of publicationCo-medication (DMARD)Patient (N)Age (years)Disease duration (years)Female (%)HAQ-DISJCTJCDAS28Jadad score
ABA* Genovese ATTAIN; 200575% MTX*39353.4±12.412.2+8.577.11.8±0.622.3±10.231.2±13.06.5±0.93
GOL Smolen GO-AFTER 50 mg; 200966% MTX461 (all) (304)55.0 (46.0–63.0)§9.6 (5.6–17.2)§741.6 (1.1-2.0) (all) (1.5 (1.1–1.9))§14.0 (9.0–25.0)§27.0 (16.0–42.0)§6.3 (5.6–7.2)§4
RTX Cohen REFLEX; 2006MTX, 16.4± 8.8 mg weekly52052.2±12.212.1±8.3811.9±0.523.4±11.833.9±15.16.9±1.05
TOC Emery RADIATE 8 mg; 2008MTX (15.7±4.4 mg)49953.9±12.712.6±9.3841.7±0.618.9±10.97.0±0.93
  • * Mixed population of patients receiving MTX (75%), and patients receiving monotherapy.

  • Subgroup of patients receiving a combination of GOL and MTX.

  • Numbers are mean±SD if not indicated otherwise.

  • § Median (IQR).

  • ABA, abatacept; DAS, Disease Activity Score; DMARD, disease modifying drugs; GOL, golimumab; HAQ-DI, Health Assessment Questionnaire-Disability Index; MTX, methotrexate; RTX, rituximab; SJC, swollen joint count; TJC, tender joint count; TOC, tocilizumab.